Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Active:	Yes
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT05797831
Trial Phases:	Phase II Phase III	Protocol IDs:	KRT-232-118 (primary) NCI-2024-03038 ENGOT en-21 GOG-3089
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Kartos Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05797831

Summary

This study evaluates navtemadlin as maintenance treatment for patients with advanced or
recurrent endometrial cancer (EC) who have achieved complete response or partial response
on chemotherapy.

The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two
different doses of navtemadlin alongside an observational control arm to determine the
Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin
Phase 3 dose compared to placebo.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.